ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BIOA
LYEL (30) RCKT (28) QTTB (53) LRMR (34) ⌘ Pro Terminal →

BioAge Labs Inc. (BIOA) — RQD Stock Rating Cockpit

$5.80 -1.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.78

BioAge Labs Inc. (BIOA) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $269.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BIOA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BIOA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, BioAge Labs Inc. (NASDAQ: BIOA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $5.80 (-1.19% 1D, market cap $269.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, BIOA ranks #758 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BIOA compare to LYEL and RCKT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BIOA carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LYEL (Lyell Immunopharma Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $270.5M) and RCKT (Rocket Pharmaceuticals Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $267.9M). Among the 5-stock peer group, QTTB leads on earnings multiple (8.9x) while QTTB leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BIOA?
▼

Per BIOA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001709941), BioAge Labs Inc. generated $9.0M in revenue (-95.9% YoY), -$80.6M in net income, and -$82.3M in free cash flow against $294.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.78 (-0.40%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510031
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (6)Whales (3)SEC (11)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.1% Base Target
$27 Bull$5 Base$4 Bear
📬 FREE BIOA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BIOA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY BIOA SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (35% of score)

Altman Z-Score 5.66 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (26% of score)

FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 43.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
23
Grade E$5.57-0.2% Next Q
Q2 (-2Q)
26
Grade E$5.56-1.6% Next Q
Q3 (-1Q)
28
Grade E$5.47+6% Next Q
Current
31
Grade E$5.80-9.4% Hist 90D α
Trajectory: E (23) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BIOA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BIOA currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.25) and Max Pain ($6.09) forces dealer call-delta covering toward $27.25.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BIOA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BIOA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 31%NO 69%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
43.630 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
5.66>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE5% OF RANGE
L: $5$5.80H: $26
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 6 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

2-of-3 Quant Analysts Bearish Warning on BIOA

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (30)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (55)

Altman-Z 5.66 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (23)

6/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like BIOA
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BIOA)

  • ✓Walkthrough of BIOA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BIOA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -65.10%🛡️ HOLDING TREND SUPPORT
2026-11-03O $5.94H $5.94L $5.80C $5.80VOL 801.4K
RES: $31.91SUP: $3.96SMA50: $7.25SMA200: $15.67
$27.43$21.30$15.17$9.04$2.91RES $31.91SUP $3.96$5.802026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BIOA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BIOA Butterfly Map → + Track BIOA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -95.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BIOA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BIOA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BIOA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BIOA)

Health Care Rank #758 of 1015 ⚔️ LYEL vs BIOA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BIOA vs. LYEL, RCKT, QTTB, LRMR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, BioAge Labs Inc. (BIOA) ranks #758 by composite RQD confidence (31/100, grade E) and #528 by equity capitalization ($269.4M). Within this direct 5-issuer industry benchmark cohort, QTTB leads on earnings valuation at 8.9x trailing P/E, while QTTB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. QTTB currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with BIOA at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BIOA ACTIVE
BioAge Labs Inc.
E 31/100 — — -35.0% -1.19% $269.4M Benchmark Subject
LYEL
Lyell Immunopharma Inc.
E 30/100 — — -35.0% -1.45% $270.5M /lyel-vs-bioa →
RCKT
Rocket Pharmaceuticals Inc.
E 28/100 — — -35.0% +1.23% $267.9M /rckt-vs-bioa →
QTTB
Q32 Bio Inc.
D+ 53/100 8.9x — 85.0% -2.24% $265.2M /qttb-vs-bioa →
LRMR
Larimar Therapeutics Inc.
E 34/100 — — -35.0% -4.05% $256.6M /lrmr-vs-bioa →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001709941 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioAge Labs Inc. (BIOA) reported GAAP revenue of $9.0M (-95.9% vs. FY2024 revenue of $218.9M , and -93.4% cumulative change since FY2023) , GAAP net income of -$80.6M, operating cash flow of -$81.6M, and free cash flow of -$82.3M (-58.7% YoY). On the balance sheet, BIOA closed FY2025 with $294.9M in total assets against $0 in total debt (Altman Z-Score: 5.66, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $9.0M -$80.6M -$81.6M -$82.3M $294.9M $0
FY2024 (FY) 2024-12-31 $218.9M -$71.1M -$51.5M -$51.9M $358.2M $2.5M
FY2023 (FY) 2023-12-31 $135.5M -$63.9M -$37.4M -$37.4M — —

3. BIOA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BIOA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, BioAge Labs Inc. (NASDAQ: BIOA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $5.80 (-1.19% 1D, market cap $269.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, BIOA ranks #758 in composite RQD confidence.

How does BIOA compare to LYEL and RCKT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BIOA carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LYEL (Lyell Immunopharma Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $270.5M) and RCKT (Rocket Pharmaceuticals Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $267.9M). Among the 5-stock peer group, QTTB leads on earnings multiple (8.9x) while QTTB leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BIOA?

Per BIOA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001709941), BioAge Labs Inc. generated $9.0M in revenue (-95.9% YoY), -$80.6M in net income, and -$82.3M in free cash flow against $294.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BIOA trading relative to its 50-day, 200-day, and 52-week technical levels?

BIOA last traded at $5.80 (-1.19% on volume of 688,964 shares), positioning the stock -20.00% below its 50-day simple moving average ($7.25) and -62.99% below its 200-day simple moving average ($15.67). Across its 52-week range of $4.81 to $25.95, BIOA sits at the 4.7% percentile with a 14-day RSI of 43.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.08 to $6.52).

Direct Sub-Reports: BIOA RQD Cockpit BIOA 12M Forecast BIOA Earnings & Move BIOA Dividends & DRIP BIOA Insiders & 13F BIOA Whale Options BIOA Profit Sankey BIOA News & Why
ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

BIOA — BioAge Labs Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

BioAge Labs Inc. (BIOA) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $5.80 (-1.19% 1D, market capitalization $269.4M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of 5.66, Piotroski F-Score of 2/9, and Debt/Equity of 0.00x.

2. Business Model, Unit Margins & SEC Financial Trajectory

BioAge Labs Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The market capitalization is $0.3B. Revenue is reported at $9.0M for FY 2025 and — for FY 2024 and FY 2023. — describes its specific products, customers, or monetization model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), BioAge Labs Inc. (BIOA) reported $9.0M in annual revenue (up from $218.9M in FY2024, -95.9% YoY) and -$80.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($135.5M revenue, -$63.9M net income) through FY2025, BIOA scaled operating cash flow to -$81.6M and free cash flow to -$82.3M, backed by $294.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $4.81 – $25.95 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — Investors should note that the graph's absence means no quantified ripple effects can be drawn from the provided data.

  • Key Question #1: Can BIOA sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $9.0M and free cash flow of -$82.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BIOA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BIOA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BioAge Labs Inc. (BIOA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BIOA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BIOA Bull vs. Bear Conversation Board — What's Your Call at $5.80?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BIOA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BIOA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $7.34 (+25.0%)
📌 Pinned Debate

Balance sheet strength, with an Altman Z-Score of 5.66 and reported cash of $188.9M against $0.0M debt, provides a financial cushion wh

Don't sleep on BIOA's setup in Health Care. Balance sheet strength, with an Altman Z-Score of 5.66 and reported cash of $188.9M against $0.0M debt, provides a financial cushion while the company funds operations.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (31/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $4.81 (-18.1%)
Spot @ $5.87

Operating margin of -60% and ROIC of -35% alongside FCF of -$82.3M in FY 2025 show the company is not yet generating cash from its oper

Sitting on the sidelines or leaning short BIOA above $5.87. Operating margin of -60% and ROIC of -35% alongside FCF of -$82.3M in FY 2025 show the company is not yet generating cash from its operations.. Until Fundamental Cash Engine (6/20) and FCF yield (0.0%) inflect higher, upside is capped near $25.95.

LIVE TAPE